Drug General Information |
Drug ID |
D0I1YH
|
Former ID |
DNC011029
|
Drug Name |
4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H15NO
|
Canonical SMILES |
C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3
|
InChI |
1S/C18H15NO/c20-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-19-11-9-15/h1-11,13,20H,12H2
|
InChIKey |
GFIBJCSJSOCGMM-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Cytochrome P450 11B1, mitochondrial |
Target Info |
Inhibitor |
[1]
|
17 alpha-hydroxylase-C17, 20-lyase |
Target Info |
Inhibitor |
[1]
|
Cytochrome P450 19 |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of steroid hormone biosynthesis
|
Glucocorticoid biosynthesis
|
Mineralocorticoid biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis
|
Androgen biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis
|
Estradiol biosynthesis II
|
Estradiol biosynthesis I
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
|
Metabolic pathways
|
Ovarian steroidogenesis
|
Prolactin signaling pathwayhsa00140:Steroid hormone biosynthesis
|
NetPath Pathway
|
FSH Signaling Pathway
|
PANTHER Pathway
|
Androgen/estrogene/progesterone biosynthesis
|
PathWhiz Pathway
|
SteroidogenesisPW000045:Androgen and Estrogen Metabolism
|
Reactome
|
Glucocorticoid biosynthesis
|
Endogenous sterolsR-HSA-193048:Androgen biosynthesis
|
Endogenous sterolsR-HSA-211976:Endogenous sterols
|
WikiPathways
|
Metapathway biotransformation
|
Oxidation by Cytochrome P450
|
Metabolism of steroid hormones and vitamin D
|
Corticotropin-releasing hormoneWP702:Metapathway biotransformation
|
Steroid Biosynthesis
|
Glucocorticoid & Mineralcorticoid Metabolism
|
Prostate Cancer
|
Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation
|
Tryptophan metabolism
|
Ovarian Infertility Genes
|
FSH signaling pathway
|
Integrated Breast Cancer Pathway
|
Phase 1 - Functionalization of compounds
|
References |
REF 1 | J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. |